top of page
Browse by category
Search
VIVUS launches QSYMIA in the UAE
VIVUS has received market approval of QSYMIA (phentermine and topiramate extended-release capsules) CIV in the United Arab Emirates (UAE)...
REDEFINE 2: CagriSema demonstrates superior weight loss
Outcomes from the from REDEFINE 2, a phase 3 trial in the global REDEFINE programme, have revealed the trial achieved its primary...
First patient dosed in the clinical study of bofanglutide injection for overweight or obesity
The first participant has been successfully dosed in Gan & Lee Pharmaceuticals’ Phase 2 clinical trial of bofanglutide (GZR18) injection,...
More than 65 organisations advocate for coverage of obesity care in open letter to leading employers as Obesity Care Week urges expanded coverage to include FDA-approved obesity medications
The Alliance for Women's Health and Prevention's (AWHP) EveryBODY Covered campaign delivered an open letter to executives at top...
Naturally occurring BRP molecule rivals semaglutide in weight loss but without side effects
Stanford University Medical Center researchers have identified a naturally occurring molecule, BRP, which appears similar to semaglutide...
Melatonin improves muscle energy efficiency offering a potential therapy to combat diabesity
An international study led by the University of Granada (UGR) has revealed that melatonin, known for its ability to regulate the...
Browse by tag
bottom of page